Just over 50 years ago, President Richard M. Nixon signed into law the National Cancer Act of 1971, which established the National Cancer Institute. Cancer had become the second leading (after heart disease) cause of death in the US in 1970. The National Cancer Institute (NCI) from its establishment had broad powers, including the creation […]
26 Comments Read MoreArticles
Cancer 2023: What’s Happening in the Combat Zone?
Payola from Portola?
In his tearjerker “Sisters of Mercy,” Leonard Cohen sings, I’ve been where you’re hanging and think I can see how you’re pinned. Although I am less inclined to bash the FDA than many, it has recently let modern medical practice place many patients in an undesirable situation. What if there was a very powerful drug, […]
932 Comments Read MoreIs This Red-Hot New “Blood Stock” Any Bloody Good as an Investment?
[Ed. Note: Dr. KSS writes about biotech stocks for the Irregulars. We have not reviewed or approved his topics or opinions, and he has agreed to our trade restrictions. Enjoy!] Twenty years ago, I was living life on an extreme slant as a medicine resident. My routine was a rut of working 36 hours, having […]
538 Comments Read MoreVIC — Charles de Vaulx (International Value Advisers)
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
Astellas Pharma is a big Japanese company - 17,000 employees...
http://www.mitobridge.com/news/publications It seems like Mitobridge out of Cambridge MA. is also looking at Mitochondri...
$KITE: Review article in Los Angeles TimesHigh-flying Kite could score big with new cancer treatment [Los Angeles T...
Medivation (MDVN) and Astellas Pharma (ALPMY)just threw out some pretty impressive data in their Phase 2 Strive trial fo...
Has anyone looked at Aveo Oncology (AVEO). After a period of disappointing news, management is reporting "significant im...
Cubist sounds like the likely candidate. But until they resolve the patent infringement against Teva (possible trial dat...